Citi, acting through Citibank N.A., has been appointed by Amryt Pharma Plc (“Amryt”) – a global, commercial-stage biopharmaceutical company dedicated to commercializing and developing novel therapeutics to treat patients suffering from serious and life-threatening rare diseases – to act as depositary bank for its American Depositary Receipt (“ADR”) programme.
Amryt’s American Depositary Shares (“ADS”) trade on the Nasdaq Global Select market under the symbol “AMYT”. Each ADS represents five ordinary shares of the company. Amryt’s underlying ordinary shares are listed and trade on AIM, a market operated by the London Stock Exchange, under the symbol “AMYT”, and on Euronext Growth, a market regulated by Euronext Growth Market Dublin, under the symbol “AYP.”
Joe Wiley, CEO of Amryt, commented: “Listing on Nasdaq is a very important milestone for Amryt and will provide us with the opportunity to improve underlying liquidity in our shares, target a wider investor audience and increase our analyst coverage. With nearly 70% of our shareholders based in North America, listing on Nasdaq is an important part of our shareholder engagement and development plans. Furthermore, we believe our Nasdaq listing will significantly assist our efforts to drive value for all our stakeholders.
Commenting on the appointment, Dirk Jones, Global Head of Issuer Services, at Citi said: “We look forward to supporting Amryt’s ADR programme and expanding the company’s investor outreach through the expertise of our leading Investor Relations Advisory team and the breadth of our global equity distribution network.”